



For Immediate Release

Oct. 27, 2006

Company Name: Dainippon Sumitomo Pharma Co., Ltd.
President: Kenjiro Miyatake
Stock Exchange Listings: Tokyo, Osaka, Nagoya
Security Code number: 4506

Revised March 2007 Interim and Fiscal-Year Financial Estimates

We would like to announce that, based on recent performance trends, the March 2007 interim and fiscal-year estimates published on May 11, 2006 have been revised as follows.

1. Revised Consolidated financial estimates

(1) Interim (April 1, 2006 to September 30, 2006)

(units: million yen, %)

	Sales	Operating income	Recurring income	Net income
Previously published estimates (A)	127,000	17,500	17,000	7,500
Current revised estimates (B)	126,900	20,500	19,600	9,500
Increase (decrease) (B — A)	(100)	3,000	2,600	2,000
Rate of change (%)	(0.1%)	17.1%	15.3%	26.7%
(for reference) Previous interim results	84,738	8,992	8,475	3,997

(2) Fiscal Year (April 1, 2006 to March 31, 2007)

(units: million yen, %)

	Sales	Operating income	Recurring income	Net income
Previously published estimates (A)	260,000	41,000	40,000	21,000
Current revised estimates (B)	260,000	42,000	40,500	22,000
Increase (decrease) (B — A)	—	1,000	500	1,000
Rate of change (%)	—	2.4%	1.3%	4.8%
(for reference) Previous results	245,783	28,885	27,235	15,377

2. Revised Non-consolidated financial estimates

(1) Interim (April 1, 2006 to September 30, 2006)

(units: million yen, %)

	Sales	Operating income	Recurring income	Net income
Previously published estimates (A)	120,000	17,300	16,800	7,400
Current revised estimates (B)	120,400	20,300	19,400	9,400
Increase/decrease (B — A)	400	3,000	2,600	2,000
Rate of change (%)	0.3%	17.3%	15.5%	27.0%
(for reference) Previous interim results	78,072	8,889	8,424	4,053

(2) Fiscal Year (April 1, 2006 to March 31, 2007)

(units: million yen, %)

	Sales	Operating income	Recurring income	Net income
Previously published estimates (A)	247,000	40,700	39,700	20,900
Current revised estimates (B)	247,000	41,700	40,200	21,900
Increase/decrease (B — A)	—	1,000	500	1,000
Rate of change (%)	—	2.5%	1.3%	4.8%
(for reference) Previous results	232,559	28,605	27,032	15,389

3. Reasons for Revisions (Consolidated and Non-consolidated)

(1) Interim Estimates

Sales projections are still as initially estimated.

Because of matters such as cost control and some shift in expenses to the second half, costs are lower than initial estimates, primarily in manufacturing costs, sales costs, and R&D costs. Operating income is now projected to be 3 billion yen higher than initially projected, and recurrent income is expected to be 2.6 billion yen higher. Special losses are also expected to be lower than initially estimated due to improvements in the retirement benefits plan. As a result, a 2 billion yen higher net income is anticipated.

(2) Fiscal-Year Estimates

Sales projections are still as initially estimated in the same manner as interim projections. In the second half, as a result of joint development costs and shifts in expenses from the first half, sales costs and general administration costs are expected to be greater than initially estimated, and the growth of fiscal-year net income is therefore expected to be lower than the interim growth.

(Note) The above estimates are based on available information at the time this report is being issued. Actual financial results may differ significantly, depending on a number of factors.